Canada Spends Logo

Explorez notre analyse du budget 2026

Grant: CIHR - ICR / Cancer Research Society Partnership - Research Grants

McGill University

$60,000.00

Unlocking new options for patients with squamous cell carcinoma of the lung

EF 2020-21

Résumé
Lung cancer is the greatest cause of cancer related death. Yet funding for lung cancer remains poor. While treatment for primary lung cancer can be intermittently effective, the vast majority of patients recur which ultimately leads to lung cancer related death. Immunotherapy has shown great promise with improved outcomes and prolonged survival in a wide variety of cancers, including lung cancer. However, approximately 60% of lung cancer patients treated with immunotherapy will fail to respond and an even larger proportion will fail to respond to chemotherapy. Therefore, this research proposal is aimed at improving these outcomes to reduce the incidence of recurrence in lung cancer patients. We have identified a new therapeutic target for squamous cell lung cancer, a type of lung cancer that affects nearly a quarter of all lung cancers. This target is currently being tested in clinical trials for breast cancer, therefore, this research proposal sets the stage for early translation to clinical trial implementation for squamous cell lung cancer. If successful, this proposal would offer the first available molecular precision medicine therapy for patients with squamous cell lung cancer, which could dramatically improve overall outcomes for these patients as well as reduce toxicity-related to treatment. Indeed, to date, unlike in adenocarcinoma, the other major type of lung cancer that accounts for 30% of all lung cancers, squamous cell carcinoma has no targeted therapies.
Programme
CIHR - ICR / Cancer Research Society Partnership - Research Grants
Bénéficiaire
Emplacement
Quebec, Canada
Type de bénéficiaire
Academia
Type
Grant
Source
CIHR Funding Decisions Database

Tel que publié

Id
453482
Name
Fiset Pierre-Olivier
Region
Québec
Country
Canada
Orgtype
Institution Paid; Research Institution
Partnername
Cancer Research Society Inc.; Cancer Research Society Inc.
Instname2
Cancer Research
Prcname2
Special Cases
Projecttitle
Unlocking new options for patients with squamous cell carcinoma of the lung
Programtype2
Operating Grants
Orgnameinp2
McGill University
Cihramount2
$60,000
Cihrequipment2
$0
Programname2
CIHR - ICR / Cancer Research Society Partnership - Research Grants
Keyworddelim
Biomarkers; Targets
Abstract
Lung cancer is the greatest cause of cancer related death. Yet funding for lung cancer remains poor. While treatment for primary lung cancer can be intermittently effective, the vast majority of patients recur which ultimately leads to lung cancer related death. Immunotherapy has shown great promise with improved outcomes and prolonged survival in a wide variety of cancers, including lung cancer. However, approximately 60% of lung cancer patients treated with immunotherapy will fail to respond and an even larger proportion will fail to respond to chemotherapy. Therefore, this research proposal is aimed at improving these outcomes to reduce the incidence of recurrence in lung cancer patients. We have identified a new therapeutic target for squamous cell lung cancer, a type of lung cancer that affects nearly a quarter of all lung cancers. This target is currently being tested in clinical trials for breast cancer, therefore, this research proposal sets the stage for early translation to clinical trial implementation for squamous cell lung cancer. If successful, this proposal would offer the first available molecular precision medicine therapy for patients with squamous cell lung cancer, which could dramatically improve overall outcomes for these patients as well as reduce toxicity-related to treatment. Indeed, to date, unlike in adenocarcinoma, the other major type of lung cancer that accounts for 30% of all lung cancers, squamous cell carcinoma has no targeted therapies.
Competitiondate
202103
Approvedterm2
2 yrs 0 mth
Pinamesdelim
Fiset, Pierre-Olivier
Approvedterm
2 ans 0 mois
Cihrcontribution2
Inst of Cancer Research~ $60,000~ $0~